Science and Engineering Research Council

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

Retrieved on: 
Tuesday, December 6, 2022

BioPIPS seeks to use research and innovation to grow Singapore's manufacturing capabilities for biologics, which include recombinant therapeutic proteins, and vaccines.

Key Points: 
  • BioPIPS seeks to use research and innovation to grow Singapore's manufacturing capabilities for biologics, which include recombinant therapeutic proteins, and vaccines.
  • Amid the COVID-19 pandemic, biologics and vaccines played a critical role globally in preventing severe disease and saving lives.
  • The consortium ultimately aims to make Singapore's biologics manufacturing capabilities best-in-class and well-positioned for the introduction of new products and novel manufacturing technologies.
  • "Riding on the success of PIPS, BioPIPS aims to enhance Singapore's innovation capabilities in biologics and vaccines manufacturing by leveraging the strengths of our leading pharmaceutical companies and institutes of higher learning.